内容紹介
Summary
Leptomeningeal metastasis(LM)is a rare complication in patients with breast cancer. We report 3 cases of LMs in patients with breast cancer who were treated with intrathecal methotrexate via an Ommaya reservoir. In 2 patients, a significant neurological improvement was observed, whereas in 1 patient there was no response. The overall survivals for the patients who experienced improvements were 22 and 9 months. Although we have no evidence for the efficacy of intrathecal chemotherapy for LMs in patients with breast cancer, its effects for some patients could be promising, after reservoir management and drug selection establishment.
要旨
乳癌由来の髄膜癌腫症(leptomeningeal metastasis: LM)は,比較的まれな病態である。本稿では,Ommaya reservoirを介して抗癌剤髄腔内投与を行った3例の乳癌髄膜癌腫症について報告した。2例では神経症状の明らかな改善を認めたが,1例では治療効果を認めなかった。症状の改善した2例の診断後生存期間は22か月と9か月であった。抗癌剤髄腔内投与の治療効果に関するエビデンスは得られていないが,今後症例選択により治療成績が向上する可能性はある。
目次
Leptomeningeal metastasis(LM)is a rare complication in patients with breast cancer. We report 3 cases of LMs in patients with breast cancer who were treated with intrathecal methotrexate via an Ommaya reservoir. In 2 patients, a significant neurological improvement was observed, whereas in 1 patient there was no response. The overall survivals for the patients who experienced improvements were 22 and 9 months. Although we have no evidence for the efficacy of intrathecal chemotherapy for LMs in patients with breast cancer, its effects for some patients could be promising, after reservoir management and drug selection establishment.
要旨
乳癌由来の髄膜癌腫症(leptomeningeal metastasis: LM)は,比較的まれな病態である。本稿では,Ommaya reservoirを介して抗癌剤髄腔内投与を行った3例の乳癌髄膜癌腫症について報告した。2例では神経症状の明らかな改善を認めたが,1例では治療効果を認めなかった。症状の改善した2例の診断後生存期間は22か月と9か月であった。抗癌剤髄腔内投与の治療効果に関するエビデンスは得られていないが,今後症例選択により治療成績が向上する可能性はある。